Eli Lilly and Company has taken the lead in in the production of tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, exhibits significant potential to improve glycemic control and reduce heart disease. The intricate production method of tirzepatide utilizes a series of precision steps to